A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2009
This article has no abstract
Epistemonikos ID: cf13293b7bcf56ddc376c5e777c8a519209c9a88
First added on: Apr 16, 2025